Project Grant HT94252410899
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$176K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded a $525,847 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to conduct advanced biomedical research on defining and exploiting essential components of the androgen receptor program operative in castration-resistant prostate cancers. The award has a performance period from July 15, 2025 to July 14, 2027. This...
The Defense Health Agency awarded a $1,927,373 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the development of targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The award duration is from February 15, 2025 to February 14, 2028. As a National Cancer Institute-designated comprehensive cancer...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $5,149,107 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research on "Defining Human Correlates of Super-Evasive Disseminated Tumor Cells, Their Pathological Relevance and How to Eradicate Them." The award period runs from July 1, 2025 to June 30, 2029. The research aims to transform healthcare for military service members,...
The Defense Health Agency awarded a $528,000 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to assess the landscape of cell surface targets in metastatic prostate cancer. This 2-year grant, which began on April 15, 2024, is funded through the Military Medical Research and Development program (CFDA 12.420). The project aims to advance biomedical research on innovative therapeutic approaches for cancer, in line with the program's goals of...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
Fred Hutchinson Cancer Center was awarded a $898,342 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 to exploit real-world clinical genomic data to discover biomarkers and address outcome disparity for prostate cancer. Through this award, Fred Hutchinson Cancer Center will leverage existing genomic and clinical data to identify biomarkers...
The Fred Hutchinson Cancer Research Center was awarded a $1,125,843 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) for the period of August 1, 2021 through July 31, 2024. Under this award, Fred Hutchinson Cancer Research Center will define and modulate BRCANESS to improve the precision of prostate cancer therapy. The Military Medical Research and Development program supports biomedical research to transform military...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $2,112,000.00 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research aimed at preventing liver metastasis by defining regulators of tumor dormancy, how they are disrupted, and how to reverse it. The research, which will take place from July 1, 2025 to June 30, 2029, seeks to transform healthcare for military service members, veterans, and the broader...
The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
This federal Project Grant award of $2,288,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Fred Hutchinson Cancer Center in Seattle, Washington to target epidermal plasticity in order to prevent triple negative breast cancer. The 4-year award, which commenced on April 1, 2025, will enable the cancer center to conduct advanced biomedical research focused on innovative approaches to preventing and...